Although the underlying association between weight reduction and liver function improvement in response to treatment with SGLT2 inhibitors has been demonstrated in animal models [29,33], associations between NAFLD severity, weight reduction, and fat distribution have not been fully elucidated in humans. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.